I6T-MC-AMAN - ClinicalTrials.gov - NCT03518086
I6T-MC-AMAN - ClinicalTrials.gov - NCT03518086
Key Requirements
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participants must have a diagnosis of ulcerative colitis for at least 3 months before the planned start date for the study medications
Participants must have moderately or severely active ulcerative colitis at the start of the study
Participants must have had unsatisfactory results with or were unable to take other therapies for UC
Participants who are female must meet birth control requirements in order to participate in the study
Participants must NOT
Participants must not have other types of inflammatory bowel disease, such as Crohn’s disease or indeterminate colitis (also known as “inflammatory bowel disease-unclassified”)
Participants must not have had surgery in the past in order to remove part of the colon
Participants must not have certain complications of ulcerative colitis. One of these is called toxic megacolon. This is a condition where the colon is abnormally enlarged or dilated, often requiring surgical treatment
Participants must not have received certain types of medications for inflammatory diseases in the past. The study doctor can determine if you have received these when they speak with you at the screening visit
Trial Summary
Conditions the trial is for
Ulcerative Colitis
What the trial is testing?
Mirikizumab, Placebo
Could I receive a Placebo?
yes
Enrollment Goal
1160
Trial Dates
March 2018 - October 2022
Trial Phase
3
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participants must have a diagnosis of ulcerative colitis for at least 3 months before the planned start date for the study medications
Participants must have moderately or severely active ulcerative colitis at the start of the study
Participants must have had unsatisfactory results with or were unable to take other therapies for UC
Participants who are female must meet birth control requirements in order to participate in the study
Participants must NOT
Participants must not have other types of inflammatory bowel disease, such as Crohn’s disease or indeterminate colitis (also known as “inflammatory bowel disease-unclassified”)
Participants must not have had surgery in the past in order to remove part of the colon
Participants must not have certain complications of ulcerative colitis. One of these is called toxic megacolon. This is a condition where the colon is abnormally enlarged or dilated, often requiring surgical treatment
Participants must not have received certain types of medications for inflammatory diseases in the past. The study doctor can determine if you have received these when they speak with you at the screening visit
Trial Summary
Conditions the trial is for
Ulcerative Colitis
What the trial is testing?
Mirikizumab, Placebo
Could I receive a Placebo?
yes
Enrollment Goal
1160
Trial Dates
March 2018 - October 2022
Trial Phase
3
Trial Locations
Hide locations not currently recruiting
By clicking the checkbox and using the map, you agree to allow Google Maps to collect your personal information in accordance with their Privacy Policy